Attorney Sean McAllister explains what regulators look for with off-label ketamine prescribing, what DEA audits examine, and where legal risk arises, plus his view of where psychedelic medicine is headed.
Running a ketamine therapy practice is about more than clinical care. It also means knowing what regulators and the DEA expect to see.
In this conversation, attorney Sean McAllister gets into what that looks like in practice, from off-label prescribing to DEA audits to the compliance mistakes he sees most often.
Sean specializes in psychedelic medicine and ketamine therapy and is licensed in California and Colorado. Over a 27-year legal career, he has worked in criminal defense, licensure defense for doctors and therapists, and cannabis business law, and he has experience with DEA audits and site inspections of clinics. He advises doctors, therapists, and clinics nationwide, and he also shares how a career that started with plans for environmental law led him into drug policy reform and, eventually, psychedelic law.
He’s practical and candid about where his experience ends and where the rules vary by state. Sean describes what he says regulators look for with off-label prescribing, including a real patient relationship, chart notes, and a reasonable basis for treatment, and why, in the disciplinary cases he has reviewed, problems tend to come from skipped basics.
You’ll also hear what DEA audits tend to examine, from running inventory records to secure storage, along with mistakes he sees, such as prescribing outside your state of practice, relying on pharmacy advice, and stretching the black bag rule.
Sean closes with his outlook on where psychedelic medicine may be headed as more compounds move toward FDA approval, and what that could mean for ketamine clinics, including his view that experience in ketamine therapy can carry over to new medicines.
Content note: this episode includes a brief discussion of suicidality in the context of clinical and legal risk.
What You'll Learn in This Episode:
A clearer picture of what Sean says regulators look for when ketamine is prescribed off-label, from a real patient relationship to chart notes and a diagnosis
What DEA audits tend to examine in his experience, including inventory records and secure storage
Common compliance mistakes he sees, such as prescribing to patients outside your state of practice, skipping registry checks, and shipping arrangements with compounding pharmacies
How he thinks about legal risk, including consent forms, patient screening, and where he says serious cases tend to come from
His outlook on how psychedelic medicines moving toward FDA approval could affect ketamine clinics
Key Takeaways:
Off-label prescribing in Sean’s view. He notes that off-label prescribing is very common and, in his view, low risk when the basics are covered: a real patient relationship, chart notes, intake forms, a medical exam, consideration of contraindications, and a diagnosis with a reasonable basis for treatment. Having surveyed disciplinary cases around the country, he says he is not aware of any that attack off-label prescribing when there is a DSM condition. The cases he does see involve skipped steps, such as no medical exam, no review of contraindications, or violating the telehealth rule. He also notes that some state regulators have taken stricter positions, so it is worth checking your own state.
What DEA audits look at. Sean says a clinic should keep a running, up-to-date inventory of controlled substances going back two years, kept in a log and not scattered across patient files, and that the log should match what is in the locked storage area. He believes inventory needs to be reconciled at least every two weeks, and he describes the penalties as potentially significant. He also says field agents are typically reasonable and will try to help a clinic come back into compliance after an honest mistake, while intentional wrongdoing is treated much more seriously.
Common compliance mistakes. He points to telehealth rules and prescribing only to patients located in your state of practice, checking the state prescription registry to screen for doctor shopping, and relying on advice from others such as compounding pharmacies instead of a DEA consultant or attorney. One example he gives is a pharmacy offering to ship a patient’s ketamine to the clinic for pickup, which he says is not allowed. He notes the telehealth rules are continually potentially being modified and says to be very careful with them.
Off-site and at-home administration. He explains that controlled substances are generally stored, dispensed, and administered where the DEA registration is located, and that the “black bag” exception is meant for random, as-needed situations. In his view, it is probably being stretched too far. He says regulators want to know how a patient was kept safe, that some states consider unsupervised at-home ketamine inadequate, and that there is not a clear answer from every regulator.
Where legal risk comes from. In his experience, a good consent form is the foundation of protecting yourself legally, with clear language on the inherent risks of ketamine, including a section on suicidality, though he notes it protects only against those inherent risks. In the cases he describes, serious lawsuits and regulatory actions have tended to involve extreme behavior, such as no medical exam, staff signing prescriptions, ignoring signs of misuse, or continuing to prescribe after a patient expressed suicidal thoughts. For a typical practitioner with proper disclosure, patient vetting, and medical monitoring, he considers the risk relatively low.
Where the field may be heading. Sean expects a number of psychedelic medicines to be FDA-approved in the coming years and says insurance coverage could be a major change. These are his predictions, not certainties. He says that experience with ketamine therapy could carry over to new compounds, though he expects each to bring its own training requirements.
Listen to the episode on Apple Podcasts, Spotify, Overcast, or on your favorite podcast platform. Watch the discussion on YouTube here.
Episode 69 show notes:
00:00:00 Teaser: Who Gets Access to Psychedelic Medicine?
00:00:21 Welcome and Meet Attorney Sean McAllister
00:02:28 From Environmental Law Plans to Drug Policy Reform
00:04:12 Cannabis Reform and the Path to Psychedelic Law
00:06:02 A 27-Year Legal Career: Criminal Defense, Licensure Defense, and DEA Audits
00:08:47 Learning on the Job and the Pioneer Mindset
00:10:53 Stigma and Psychedelics Moving From Counterculture to Culture
00:15:28 Riding the Wave: How a Psychedelic Lawyer's Role May Evolve
00:17:26 Off-Label Ketamine Prescribing: What Are the Legal Bounds?
00:20:01 What Regulators Look For: Patient Relationship, Chart Notes, and a Diagnosis
00:23:48 Disciplinary Cases, Skipped Basics, and State Differences
00:25:21 Training and Experiencing the Medicine: The Regulatory Perspective
00:30:34 Shifting to the DEA: What Does an Audit of a Ketamine Clinic Look Like?
00:33:19 Inventory Records: The Two-Year Running Log and Secure Storage
00:37:01 Common Compliance Mistakes: State of Practice, Telehealth, and the Registry
00:38:39 Pharmacy Advice and Shipments to the Clinic
00:40:28 The Black Bag Rule and Off-Site Administration
00:44:30 Lawsuits and Consent Forms: What Patterns Does an Attorney See?
00:46:25 Where Serious Cases Tend to Come From
00:51:03 What FDA Approvals Could Mean for Ketamine Clinics
00:53:54 Why a Full Suite of Services May Matter, and Skills That Transfer
00:56:10 Access, Insurance Coverage, and Hope for Broader Healing
00:57:13 Co-Creating the Future: A Call to Get Involved
00:58:40 Rapid-Fire Questions Begin
01:03:07 Where to Find Sean McAllister
01:05:04 Episode Ending
Thanks for Listening
Connect with Sean T. McAllister
Website - https://mcallisterlawoffice.com/about/
Instagram - https://www.instagram.com/mcallister2928/
If you enjoyed this episode check these out too
Episode 023 – Mastering Clinic Compliance: Insights from Retired DEA Agent Dennis Wichern
Sam talks with Dennis Wichern, a retired DEA special agent who now runs Prescription Drug Consulting, about what DEA audits focus on, record keeping essentials, and how telehealth has affected controlled substance regulations. A good companion to this conversation if you want a former agent's perspective on compliance.
Psychiatrist Dr. Scott Shannon shares his perspective on what happens after a ketamine therapy session, including integration, psychotherapy, and durability, along with his advice on building a practice around a philosophy of care.
Psychedelic Alpha: Data-driven insights on psychedelic drug development, regulation, policy, and research, including the clinical trial list Sean mentioned.
Professional Education Disclaimer: This content is intended for licensed healthcare professionals and clinic operators and should not be used by patients for self-treatment or self-education. The information presented reflects the individual experience and perspective of the guest, an attorney, and is general information only. It is not legal advice, and listening to or reading this content does not create an attorney-client relationship. Laws, regulations, and enforcement practices vary by state and change over time, and nothing here replaces advice from your own attorney, compliance consultant, or licensing board about your specific situation. Healthcare providers must conduct their own due diligence, consult current literature and current regulations, and evaluate their practices within their specific regulatory environment. This content does not constitute medical advice for specific patients or clinical situations. Treatment decisions should always be based on individual patient assessment and adherence to professional medical standards.
Who is attorney Sean McAllister?
Sean McAllister is an attorney who specializes in psychedelic medicine, ketamine therapy, and other related and adjacent industries. He is licensed in California and Colorado. On Episode 69 of the Ketamine Startup Podcast, he describes a 27-year legal career that includes criminal defense, licensure defense for doctors and therapists, and cannabis business law. He says he advises doctors, therapists, and clinics, including on ketamine, and has experience with DEA audits and site inspections of clinics.
What do regulators look for when ketamine is prescribed off-label?
According to attorney Sean McAllister, off-label prescribing is a common practice, and the standard is fairly broad: the provider should have a reasonable basis, from their training and expertise, to believe the medication could benefit the patient. In his experience, regulators want to see a real patient-provider relationship, chart notes, intake forms, a medical exam, consideration of contraindications, and a diagnosed condition that supports the prescription. He notes that some state regulators have taken stricter positions, so he suggests checking with your own state board.
What do DEA audits of ketamine clinics tend to examine?
In his experience with DEA site inspections, attorney Sean McAllister says inspectors expect to see a running inventory of controlled substances going back two years, kept in a log and not scattered across patient files, along with a locked or otherwise secure storage area. He says the log should match what is actually in storage, and that mismatches or missing records can trigger further investigation. He also says DEA field agents are typically reasonable and want clinics to be in compliance.
What common compliance mistakes does Sean McAllister flag for ketamine clinics?
Attorney Sean McAllister points to prescribing to patients outside your state of practice, skipping the state controlled substances registry check, and relying on pharmacy advice without confirming it with a DEA consultant or attorney. He also flags clinics accepting patient-specific shipments from a compounding pharmacy, and says the “black bag” exception, which he describes as meant for random, as-needed situations, can be stretched too far. He says the telehealth rules may continue to change, so he urges care.